FDA Clears Expanded Access Program for StemCyte's Cord Blood Therapy Following Successful Long COVID Trial
核心洞察
The FDA has cleared an expanded access program for StemCyte (搜索)'s RegeneCyte cord blood therapy, enabling eligible Long COVID (搜索) patients to access treatment outside of clinical trials.
Phase IIa trial results showed 85% of Long COVID (搜索) patients treated with RegeneCyte experienced complete relief from chronic fatigue (搜索), compared to only 20% in the placebo group.
The therapy demonstrated a favorable safety profile with only 10% of treated patients experiencing mild treatment-emergent adverse events that resolved within one hour.
The U.S. Food and Drug Administration has cleared an expanded access program for StemCyte (搜索)'s RegeneCyte, a hematopoietic progenitor cell therapy (搜索) derived from cord blood, marking a significant milestone for Long COVID (搜索) patients who have exhausted standard treatment options. The clearance follows compelling Phase IIa clinical trial data demonstrating the therapy's efficacy in treating post-acute sequelae of SARS-CoV-2 (搜索).
Phase IIa Trial Demonstrates Strong Efficacy Signal
The randomized, single-blind, placebo-controlled Phase IIa study enrolled 30 participants, with 22 receiving RegeneCyte treatment and 10 receiving placebo. The trial's most striking finding was that 85% of patients treated with the cord blood therapy experienced complete relief from chronic fatigue (搜索) symptoms, compared to just 20% in the placebo group, meeting the study's secondary endpoints.
"The FDA's clearance of this program is a significant validation of the safety and therapeutic potential of RegeneCyte, our HPC-cord blood product," said Dr. Tong-Young Lee, CEO of StemCyte (搜索). "With our RMAT (Regenerative Medicine Advanced Therapy) designation already in place, this program allows us to bridge the gap for patients in need as we continue advancing RegeneCyte through the clinical development and regulatory pathway."
The study utilized the Chalder Fatigue Questionnaire (CFQ-11) to measure fatigue severity and showed significant improvements in overall fatigue symptoms, fatigue severity, and physical fatigue among treated patients. Additional assessments using the Patient Global Impression of Severity (PGI-S) scale confirmed significant improvements in fatigue symptoms at weeks 12, 18, and 26 compared to placebo.
Safety Profile Supports Clinical Development
The trial met its primary safety endpoint based on treatment-emergent adverse events (TEAEs). In the RegeneCyte group, only 2 of 20 participants experienced mild TEAEs with no severe adverse events, resulting in a 10% incidence rate. All adverse events resolved within one hour of treatment. The placebo group showed a 20% incidence rate of TEAEs, with all events unrelated to treatment and resolving with appropriate care.
Cognitive function assessments using the Montreal Cognitive Assessment (MoCA) showed modest improvements, with average scores increasing from 24 at baseline to 26 at weeks 12 and 26, though these changes were not statistically significant compared to placebo.
Addressing Critical Unmet Medical Need
The expanded access program targets patients with serious or life-threatening Long COVID (搜索) symptoms who have exhausted standard treatment options. StemCyte (搜索) will work directly with treating physicians to facilitate access under the FDA's compassionate use framework.
Long COVID (搜索) affects patients with more than 200 documented symptoms that can persist, worsen, or recur over time. Common manifestations include extreme fatigue, brain fog, lightheadedness, problems with taste or smell, sleep disturbances, shortness of breath, and cardiovascular complications. The condition can lead to secondary diagnoses including heart disease, mood disorders, postural orthostatic tachycardia syndrome, and myalgic encephalomyelitis/chronic fatigue (搜索) syndrome.
Unique Position in Long COVID Treatment Landscape
RegeneCyte represents the only FDA-licensed cord blood product currently being evaluated in U.S. clinical trials specifically for Long COVID (搜索) treatment. The therapy is an allogeneic cord blood-derived hematopoietic progenitor cell treatment traditionally used in unrelated donor transplants to restore blood and immune function in patients with inherited or acquired blood disorders.
Based on the promising Phase IIa results, StemCyte (搜索) plans to accelerate RegeneCyte's development and is in ongoing discussions with the FDA to advance to the next phase of clinical trials. The company's transition from a premier cord blood bank to a leader in regenerative cell therapy positions it uniquely in the emerging Long COVID (搜索) treatment space.